Medibio Enters Into an Agreement with Otsuka Pharmaceutical Development & Commercialization, Inc.
Medibio’s Depression Diagnostic Ready for FDA Confirmatory Study. (Aug 2 2017)
Medibio Initiates Enrollment for Its Depression Diagnostic Confirmatory Study to Support FDA Clearance (Aug 21 2017)
The Honourable Patrick Kennedy Appointed to Medibio Board of Directors (2 Jul 2017)
Independent researchers present first data validating Medibio’s technology at the prestigious “Sleep 2017” (8 Jun 2017)
Scientific breakthrough on objective diagnosis of PTSD (27 Jun 2017)
Medibio signs strategic joint Development Agreement with Mayo Clinic.
Medibio appoints experienced US based med-tech CFO (21 Apr 2017)
Appointment of Non Executive Director & Advisory Board Chang (1 Feb 2017)
Partnership with leading US University on Post Traumatic Stress Disorder (25 Jan 2017)
Early Repayment of Convertible Note (30 Jan 2017)
Medibio’s Depression Diagnostic demonstrates excellent performance in the pilot phase of its US Validation Study (21 Dec 2016)
University of Ottawa Depression Study improves accuracy rate to an outstanding 86% in a far larger sample.(Nov 16)
Capital raising of $13.5 million to accelerate growth (Nov 16)
MEB and Monash establish groundbreaking partnership on innovation for sleep and mental health solution (September 2016)